Equities analysts predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post earnings per share of ($0.20) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sangamo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.35). Sangamo Therapeutics reported earnings of ($0.15) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 33.3%. The firm is scheduled to issue its next earnings results on Thursday, February 28th.
On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.72) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.61). For the next fiscal year, analysts forecast that the company will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.32) to ($0.49). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. The firm had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The business’s quarterly revenue was up 99.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.15) EPS.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 12,250 shares in the company, valued at $122,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders sold 30,000 shares of company stock worth $350,150. 1.20% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in shares of Sangamo Therapeutics by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock valued at $1,792,000 after acquiring an additional 7,817 shares during the period. MetLife Investment Advisors LLC increased its position in shares of Sangamo Therapeutics by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 73,166 shares of the biopharmaceutical company’s stock valued at $1,240,000 after acquiring an additional 26,009 shares during the period. United Services Automobile Association increased its position in shares of Sangamo Therapeutics by 9.2% in the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock valued at $818,000 after acquiring an additional 4,860 shares during the period. BlackRock Inc. increased its position in shares of Sangamo Therapeutics by 3.0% in the third quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock valued at $141,063,000 after acquiring an additional 239,190 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Sangamo Therapeutics by 14.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock valued at $8,032,000 after acquiring an additional 71,134 shares during the period. Hedge funds and other institutional investors own 63.13% of the company’s stock.
NASDAQ:SGMO traded up $0.33 during trading hours on Monday, reaching $11.62. The company’s stock had a trading volume of 1,090,866 shares, compared to its average volume of 1,912,362. Sangamo Therapeutics has a 1 year low of $9.00 and a 1 year high of $27.50. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Further Reading: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.